These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31424613)

  • 1. Targeting an EGFR Water Network with 4-Anilinoquin(az)oline Inhibitors for Chordoma.
    Asquith CRM; Maffuid KA; Laitinen T; Torrice CD; Tizzard GJ; Crona DJ; Zuercher WJ
    ChemMedChem; 2019 Oct; 14(19):1693-1700. PubMed ID: 31424613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
    Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of the 4-anilinoquin(az)oline scaffold as epidermal growth factor receptor (EGFR) inhibitors for chordoma utilizing a toxicology profiling assay platform.
    Bieberich AA; Laitinen T; Maffuid K; Fatig RO; Torrice CD; Morris DC; Crona DJ; Asquith CRM
    Sci Rep; 2022 Jul; 12(1):12820. PubMed ID: 35896603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity.
    Liu F; Tang B; Liu H; Li L; Liu G; Cheng Y; Xu Y; Chen W; Huang Y
    Anticancer Agents Med Chem; 2016; 16(12):1652-1664. PubMed ID: 27039919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
    Asquith CRM; Naegeli KM; East MP; Laitinen T; Havener TM; Wells CI; Johnson GL; Drewry DH; Zuercher WJ; Morris DC
    J Med Chem; 2019 May; 62(9):4772-4778. PubMed ID: 30973735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hybrids of Quinoline and Anilinopyrimidine: Novel EGFRT790M Inhibitors with Antiproliferative Activity against Non-Small Cell Lung Cancer Cell Lines.
    Han C; Ren J; Su F; Hu X; Li M; Wang Z; Wu L
    Anticancer Agents Med Chem; 2020; 20(6):724-733. PubMed ID: 32116203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New acrylamide-substituted quinazoline derivatives with enhanced potency for the treatment of EGFR T790M-mutant non-small-cell lung cancers.
    Liu Z; Wang L; Feng M; Yi Y; Zhang W; Liu W; Li L; Liu Z; Li Y; Ma X
    Bioorg Chem; 2018 Apr; 77():593-599. PubMed ID: 29482151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells.
    Ismail RSM; Abou-Seri SM; Eldehna WM; Ismail NSM; Elgazwi SM; Ghabbour HA; Ahmed MS; Halaweish FT; Abou El Ella DA
    Eur J Med Chem; 2018 Jul; 155():782-796. PubMed ID: 30047410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway.
    Tong X; Jiang P; Li Y; Guo L; Zhang HM; Zhang BK; Yan M
    Chem Pharm Bull (Tokyo); 2019 Aug; 67(8):864-871. PubMed ID: 31142691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (H
    Zheng YG; Zhang WQ; Meng L; Wu XQ; Zhang L; An L; Li CL; Gao CY; Xu L; Liu Y
    Eur J Med Chem; 2020 Sep; 202():112522. PubMed ID: 32619886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 4,6-pyrimidinediamine derivatives as novel dual EGFR/FGFR inhibitors aimed EGFR/FGFR1-positive NSCLC.
    Xie Z; Wu K; Wang Y; Pan Y; Chen B; Cheng D; Pan S; Guo T; Du X; Fang L; Wang X; Ye F
    Eur J Med Chem; 2020 Feb; 187():111943. PubMed ID: 31846829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.
    Scheipl S; Barnard M; Cottone L; Jorgensen M; Drewry DH; Zuercher WJ; Turlais F; Ye H; Leite AP; Smith JA; Leithner A; Möller P; Brüderlein S; Guppy N; Amary F; Tirabosco R; Strauss SJ; Pillay N; Flanagan AM
    J Pathol; 2016 Jul; 239(3):320-34. PubMed ID: 27102572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combination of 4-anilinoquinazoline and cinnamic acid: a novel mode of binding to the epidermal growth factor receptor tyrosine kinase.
    Li DD; Lv PC; Zhang H; Zhang HJ; Hou YP; Liu K; Ye YH; Zhu HL
    Bioorg Med Chem; 2011 Aug; 19(16):5012-22. PubMed ID: 21763148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor.
    Zhang X; Peng T; Ji X; Li J; Tong L; Li Z; Yang W; Xu Y; Li M; Ding J; Jiang H; Xie H; Liu H
    Bioorg Med Chem; 2013 Dec; 21(24):7988-98. PubMed ID: 24183742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors.
    Wei H; Duan Y; Gou W; Cui J; Ning H; Li D; Qin Y; Liu Q; Li Y
    Eur J Med Chem; 2019 Nov; 181():111552. PubMed ID: 31387063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and Synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents.
    Allam HA; Aly EE; Farouk AKBAW; El Kerdawy AM; Rashwan E; Abbass SES
    Bioorg Chem; 2020 May; 98():103726. PubMed ID: 32171987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a prominent dual-target DDR1/EGFR inhibitor aimed DDR1/EGFR-positive NSCLC.
    Wang X; Lu Y; Chen S; Zhu Z; Fu Y; Zhang J; He J; Huang L; Luo L; Guo W; Xu Z; Xie Z; Xu X; Zhang Y; Ye F; Ma S
    Bioorg Chem; 2024 Aug; 149():107500. PubMed ID: 38823310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents.
    Yassen AS; Elshihawy HE; Said MM; Abouzid KA
    Chem Pharm Bull (Tokyo); 2014; 62(5):454-66. PubMed ID: 24789927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
    Ban HS; Tanaka Y; Nabeyama W; Hatori M; Nakamura H
    Bioorg Med Chem; 2010 Jan; 18(2):870-9. PubMed ID: 19969465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors.
    Liu LT; Yuan TT; Liu HH; Chen SF; Wu YT
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6373-7. PubMed ID: 17889528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.